Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Champions Oncology Inc Market Cap
The Champions Oncology Inc (CSBR) share price is expected to increase by 30.15% over the next year. This is based on calculating the average 12-month share price estimate provided by 1 stock analysts who have covered CSBR. Price targets range from $6 at the low end to $6 at the high end. The current analyst consensus for CSBR is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 1 Wall Street analysts have assigned CSBR 1 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Champions Oncology Inc to outperform the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on CSBR. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of CSBR.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Matt Hewitt Craig-Hallum | Buy | $6 | Upgrade | Sep 12, 2024 |
| Matt Hewitt Craig-Hallum | Hold | Downgrade | Mar 13, 2024 | |
| Scott Henry Roth MKM | Buy | $7.5 | Maintains | Sep 22, 2023 |
Roth Capital | Buy | $16 | Maintains | Mar 15, 2021 |
Benchmark | Speculative Buy | Initiates | Nov 18, 2019 | |
Roth Capital | Buy | Initiates | Sep 20, 2019 | |
Janney Montgomery Scott | Neutral | Downgrade | Jul 24, 2019 | |
Janney Capital | Neutral | Downgrade | Jul 24, 2019 | |
Craig-Hallum | Buy | Initiates | Jul 17, 2018 | |
Dawson James | Buy | Initiates | May 15, 2018 |
When did it IPO
2007
Staff Count
210
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Dr. Ronnie Morris M.D.
Market Cap
$62.7M
In 2023, CSBR generated $53.9M in revenue, which was a increase of 9.69% from the previous year. This can be seen as a signal that CSBR's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 05 Dec 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Champions Oncology, Inc. (NASDAQ:CSBR) will report Q2 financial results on December 11, 2024, after market close, followed by a conference call at 4:30 PM.
Why It Matters - Champions Oncology's upcoming financial results may impact stock performance, influencing investor sentiment and potential price movements based on operational success and market expectations.
Wed, 16 Oct 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Champions Oncology, Inc. has entered a licensing agreement with Weill Cornell Medicine to distribute hematological patient-derived xenograft models, enhancing its preclinical oncology solutions.
Why It Matters - Champions Oncology's licensing deal with Weill Cornell expands its product offerings in oncology, potentially enhancing revenue streams and market position, attracting investor interest.
Wed, 11 Sep 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Champions Oncology, Inc. (NASDAQ:CSBR) will hold its Q1 2025 Earnings Conference Call on September 11, 2024, at 4:30 PM ET. Key participants include CEO Ronnie Morris and CFO David Miller.
Why It Matters - Champions Oncology's Q1 2025 earnings call signals upcoming financial performance insights, influencing stock valuation and investor sentiment in the biotech sector.
Wed, 11 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Champions Oncology, Inc. (NASDAQ:CSBR) reported Q1 fiscal 2025 revenue of $14.1 million, up 12%, with a margin of 50%. Adjusted EBITDA was $2.0 million and net income reached $1.3 million.
Why It Matters - Champions Oncology's revenue growth and improved margins indicate a recovery trend, potentially boosting investor confidence and stock performance as the company navigates past downturns.
Mon, 09 Sep 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Champions Oncology, Inc. (CSBR) will report Q1 financial results on September 11, 2024, after market close, followed by a conference call at 4:30 PM.
Why It Matters - Champions Oncology's upcoming financial report and conference call could impact stock performance, as investors will assess growth, profitability, and future outlook in the oncology sector.
Thu, 18 Jul 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - Champions Oncology, Inc. (NASDAQ: CSBR) will host its Q4 2024 earnings conference call on July 18, 2024, at 4:30 PM ET, featuring CEO Ronnie Morris and CFO David Miller.
Why It Matters - Champions Oncology's Q4 earnings call could reveal key financial performance metrics, growth strategies, and market positioning, influencing stock valuation and investor sentiment.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
